PSA (Prostate Specific Antigen) – Total is a blood test that measures the total amount of prostate-specific antigen (PSA) in your bloodstream. PSA is a protein made mainly by cells in the prostate gland (a small gland below the bladder in people assigned male at birth). A small amount of PSA normally leaks into the blood, and levels can change with age and prostate size.

This PSA test is often described as a “prostate screen,” but it is best understood as a prostate health marker rather than a cancer-only test. A higher-than-expected total PSA can be seen with many non-cancer causes, such as an enlarged prostate (benign prostatic hyperplasia, BPH), prostatitis (inflammation or infection of the prostate), or recent prostate stimulation. Prostate cancer can also raise PSA, but PSA alone cannot confirm or rule out cancer.

In plain language: a lower PSA level is generally reassuring, while a higher or rising PSA level may prompt your clinician to look more closely at the prostate. What matters most is your result in context—your age, symptoms, prostate exam findings, medications, and whether PSA is stable or increasing over time. If the PSA is elevated, your clinician may recommend repeating the test, doing a digital rectal exam (DRE), considering additional tests (such as free PSA, PSA density, PSA velocity, MRI), or referring you to a urologist to determine whether a biopsy is needed.

Because PSA can fluctuate, your provider may also ask about factors that can temporarily increase PSA, such as a recent urinary tract infection, prostatitis symptoms, ejaculation within the last day or two, recent cycling, urinary catheter use, cystoscopy, or prostate procedures. Certain medications—especially 5-alpha-reductase inhibitors like finasteride or dutasteride—can lower PSA and may change how results are interpreted.

A total PSA blood test is commonly ordered to evaluate the prostate when there are symptoms, risk factors, or an abnormal prostate exam. It is also used to monitor known prostate conditions over time.

Your clinician may order a PSA test for reasons such as:

Prostate cancer screening (shared decision-making): Many people get a PSA test as part of prostate cancer screening, especially between ages 50–69, or earlier for higher-risk individuals. Screening decisions should consider personal values and risk because PSA screening can lead to additional testing and procedures.

Symptoms that may suggest a prostate problem: urinary symptoms are common reasons for PSA testing, including frequent urination (especially at night), weak stream, hesitancy, starting/stopping, urgency, painful urination, or difficulty emptying the bladder. Blood in the urine or semen, pelvic discomfort, or painful ejaculation may also prompt evaluation.

Abnormal findings on a digital rectal exam (DRE): If a clinician feels a lump, firmness, or asymmetry of the prostate, PSA testing can help guide next steps.

Monitoring after a prostate cancer diagnosis or treatment: PSA is widely used to monitor response to treatment (surgery, radiation, hormone therapy) and to watch for recurrence. Trends over time are often more informative than a single reading.

Higher-risk groups: PSA testing is often considered earlier or more frequently if you have a strong family history of prostate cancer (father, brother, or multiple relatives), known genetic risk (such as BRCA1/BRCA2 or other hereditary cancer syndromes), or if you are of African ancestry—groups that may have higher risk of developing aggressive prostate cancer.

• Prostate cancer
• Benign prostatic hyperplasia (BPH) / enlarged prostate
• Prostatitis (acute or chronic inflammation/infection of the prostate)
• Urinary tract infection (UTI) and other causes of urinary inflammation that can temporarily raise PSA
• Urinary retention or bladder outlet obstruction related to prostate enlargement

• Prostate cancer screening and early detection planning (individualized “prostate screen” strategy)
• Evaluating urinary symptoms to support diagnosis and treatment of prostate enlargement (BPH)
• Monitoring prostate health over time, especially when PSA trends are changing
• Follow-up and surveillance after prostate cancer treatment to help detect recurrence early
• Guiding conversations about risk reduction and preventive care in higher-risk individuals (family history/genetic risk)